Staff at a leading national firm have proudly announced the continuation of their partnership with the charity Brain Tumour Research, marking the start of a second year dedicated to raising crucial funds and increasing public awareness in the urgent quest to find a cure for brain tumours.
Sustained Commitment to a Vital Cause
As part of its ongoing and heartfelt support, colleagues at Dalcour Maclaren, a prominent utility and infrastructure consultancy with 20 offices across the UK and Republic of Ireland employing 600 people, are enthusiastically preparing to participate in Brain Tumour Research's iconic Wear a Hat Day on Friday, March 27. This initiative plays a key role in fostering conversations and generating essential financial support for groundbreaking research.
The organisation is actively encouraging other businesses, local communities, and individuals nationwide to get involved by simply donning a hat and helping to spark important discussions about brain tumour research. This collective effort underscores the power of community action in tackling significant health challenges.
Impressive Fundraising Achievements
Through dedicated charity runs and a variety of innovative fundraising activities, Dalcour Maclaren has successfully raised more than £50,000 in 2025 alone. This remarkable sum has contributed the equivalent of 17 days of vital, life-saving research, directly supporting Brain Tumour Research's mission to accelerate progress towards better treatments and, ultimately, a cure for this devastating disease.
Speaking about the renewed partnership, James Neil, CEO of Dalcour Maclaren, expressed his enthusiasm: "We are incredibly happy and excited to be entering our second year of partnership with Brain Tumour Research. Knowing that our fundraising has already helped fund 17 days of vital research shows the real difference our people are making, and we're determined to build on this momentum throughout the year."
"The Dalcour Maclaren team has really pulled together in such a fantastic way to raise more than £50k in 2025 and we are looking to go beyond this in 2026 for this amazing charity that is trying to beat this truly horrific disease," he added, highlighting the team's collective spirit.
Upcoming Challenges and Personal Inspiration
Looking ahead, Dalcour Maclaren is also preparing for a major fundraising endeavour, with a team of five colleagues set to take on the iconic TCS London Marathon on 26 April. This challenge aims to raise further funds and shine a powerful spotlight on the urgent need for increased research investment into brain tumours.
The partnership is deeply inspired by employees whose lives have been directly and tragically affected by brain tumours. Sam Horsler, a 31-year-old Executive PA from Brackley, Northamptonshire, nominated the charity after losing her mother, Sue Horsler, in 2020 to a glioblastoma – an aggressive type of brain tumour with a prognosis of just 12 to 18 months.
Sam shared her poignant story: "Everything happened so fast; Mum died just three months after being diagnosed. I remember finding the Brain Tumour Research website at the time and being shocked to read that only 1% of the national spend on cancer research has been allocated to brain tumours. That statistic stuck with me. I knew I had to do more, and I was thrilled when my colleagues chose to support this cause."
The Stark Reality of Brain Tumour Research Funding
It is a sobering fact that brain tumours kill more children and adults under the age of 40 than any other cancer in the UK. Despite this, historical records since 2002 show that just 1% of the national spend on cancer research has been allocated to brain tumours, highlighting a critical funding gap that charities like Brain Tumour Research are striving to address.
By continuing its partnership into a second year, Dalcour Maclaren reinforces its long-term commitment to making a tangible difference and playing an instrumental part in the global search for a cure. Funds raised will directly contribute to Brain Tumour Research's network of dedicated research centres across the UK, bringing renewed hope to patients and families affected by the disease.
A Collaborative Path Forward
Emphasising the importance of united efforts, Dan Knowles, CEO of Brain Tumour Research, stated: "Partnership and working together is the way forward if we are going to accelerate progress and ultimately find a cure for brain tumours. Support from organisations like Dalcour Maclaren is vital to helping us move closer to that goal."
Brain Tumour Research is committed to funding sustainable research at its dedicated centres in the UK. The charity also campaigns vigorously for the Government and larger cancer charities to invest more in research into brain tumours, aiming to speed up the development of new treatments for patients and, ultimately, to find a cure. It is the driving force behind the call for a national annual spend of £35 million to improve survival rates and patient outcomes, bringing them in line with other cancers such as breast cancer and leukaemia.
